Overview

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

Status:
Completed
Trial end date:
2018-09-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Forest Laboratories
Treatments:
Fluoxetine
Vilazodone Hydrochloride